Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Decisions of the Annual General Meeting September 16, 2020 at 3:30 pm local time (EET)

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday September 16, 2020 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2019. The remuneration policy for the company’s members of the Board of Directors and President & CEO presented to the Annual General Meeting was approved by the Annual General Meeting.

Distribution of dividends

The AGM resolved in accordance with the proposal of the Board of Directors that no dividend is paid for the financial period ended on December 31, 2019.

Members of the Board of Directors

The AGM resolved that seven (7) members are elected to the Board of Directors and that professor Osmo Suovaniemi, CEO Franco Aiolfi, emeritus professor Matti Härkönen, Commercial Counsellor Eero Lehti, Ph.D. Lea Paloheimo, CEO Liu Feng and professor Timo Joensuu are elected as members of the Board of Directors until the end of the next AGM. 

Additionally, the AGM resolved that the Chairman of the Board of Directors and the other Board members are paid a meeting fee of EUR 1,500.   

Election of the Auditor and remuneration for the Auditor

The AGM elected authorized public accountants PricewaterhouseCoopers Oy as the company’s auditor until the end of the next AGM and that the auditor is paid remuneration according to invoice presented by the auditor.

Authorization of the Board of Directors to decide on the issue of shares and to issue special rights entitling the receipt of shares

The AGM resolved to authorise the Board of Directors to decide on the issue of shares and to issue special rights referred to in Chapter 10, section 1 of the Limited Liability Companies Act entitling the receipt of shares with the following terms and conditions:

The maximum number of new Series B shares to be issued pursuant to the special rights is 3,000,000, which corresponds to approximately 24.9% of the company’s all existing Series B shares.

The authorisation includes the Board of Directors’ entitlement to decide on all terms and conditions regarding the issue of special rights. The share issue and the issue of special rights entitling to the receipt of shares can occur in derogation from the pre-emptive subscription right of the shareholders (direct share issue).

The authorisation remains valid for two (2) years from the resolution of the AGM. This authorisation replaces the former authorisations.

All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by September 21, 2020 on the company’s website (www.biohithealthcare.com/investors) and at the corporate headquarters of Biohit Oyj, located at Laippatie 1, 00880 Helsinki.

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com